Drug class
Wound Healing, Topical Growth Factor
Wound Healing, Topical Growth Factor is a compendial therapeutic drug category primarily representing topically applied recombinant growth factors, most notably recombinant human platelet-derived growth factor such as becaplermin. Read more about Wound Healing, Topical Growth Factor
1 drugs in this class 1 manufacturers
Drugs in Wound Healing, Topical Growth Factor
Wound Healing, Topical Growth Factor is a compendial therapeutic drug category primarily representing topically applied recombinant growth factors, most notably recombinant human platelet-derived growth factor such as becaplermin.
These agents mimic endogenous growth factors by binding to specific cellular surface receptors to stimulate chemotaxis, fibroblast and inflammatory cell proliferation, and angiogenesis, thereby accelerating the formation of granulation tissue in non-healing wounds.
In clinical practice, this class is primarily indicated as an adjunct to standard wound management for chronic, full-thickness neuropathic diabetic foot and lower-extremity ulcers that possess adequate tissue perfusion.
-
connectrx.com
Wound Healing, Topical Growth Factor is a compendial therapeutic drug category primarily representing topically applied recombinant growth factors, most notably recombinant human platelet-derived growth factor such as becaplermin
-
nih.gov
Wound Healing, Topical Growth Factor is a compendial therapeutic drug category primarily representing topically applied recombinant growth factors, most notably recombinant human platelet-derived growth factor such as becaplermin These agents mimic endogenous growth factors by binding to specific cellular surface receptors to stimulate chemotaxis, fibroblast and inflammatory cell proliferation, and angiogenesis, thereby accelerating the formation of granulation tissue in non-healing wounds In cl...
-
fda.gov
Wound Healing, Topical Growth Factor is a compendial therapeutic drug category primarily representing topically applied recombinant growth factors, most notably recombinant human platelet-derived growth factor such as becaplermin These agents mimic endogenous growth factors by binding to specific cellular surface receptors to stimulate chemotaxis, fibroblast and inflammatory cell proliferation, and angiogenesis, thereby accelerating the formation of granulation tissue in non-healing wounds
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.